Skip to main content

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial



Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis. This has been evidenced in preclinical models, with an inhibitory effect of anticoagulants on cancer growth through proliferative, angiogenic, apoptotic, cancer stem cell and metastatic processes. The extrinsic clotting pathway is also more upregulated in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative breast cancer subgroup, with increased tumour stromal expression of the coagulation factors Tissue Factor and thrombin.

Rivaroxaban (Xarelto®, Bayer AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa inhibitor that is routinely prescribed for the prevention of stroke in non-valvular atrial fibrillation and for both VTE prophylaxis and treatment. This trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients.


This UK-based preoperative window-of-opportunity phase II randomised control trial will randomise 88 treatment-naïve early breast cancer patients to receive 20 mg OD Rivaroxaban treatment for 11 to 17 days or no treatment. Treatment will be stopped 24 h (range 18–36 h) prior to surgery or repeat core biopsy. All patients will be followed up for 2 weeks following surgery or repeat core biopsy.

The primary endpoint is change in tumour Ki67. Secondary outcome measures include tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation.


Laboratory evidence supports an anti-cancer role for anticoagulants; however, this has failed to translate into survival benefit when trialled in patients with metastatic disease or poor prognosis cancers, such as lung cancer. Subgroup analysis supported a potential survival benefit in better prognosis advanced disease patients. This is the first study to investigate the anti-cancer effects of anticoagulants in early breast cancer.

Trial registration

UK National Research Ethics Service (NRES) approval 15/NW/0406, MHRA Clinical Trials Authorisation 48380/0003/001-0001. The sponsor is Manchester University NHS Foundation Trust, and the trial is co-ordinated by Cancer Research UK Liverpool Cancer Trials Unit (LCTU). EudraCT 2014-004909-33, registered 27 July 2015. ISRCTN14785273.

Peer Review reports


Breast cancer in women is associated with a four-fold increased risk of venous thromboembolism (VTE) compared to age-matched women without cancer [1, 2]. Chemotherapy-induced VTE occurs in up to 7% of early breast cancer and 17% of metastatic breast cancer patients [3]. Breast cancer patients who develop VTE have a worse survival, which cannot solely be accounted for by VTE-induced mortality [4, 5]. It is thought to in part be due to a promotion of cancer growth and metastasis by coagulation factors.

Tissue Factor (TF), a transmembrane glycoprotein, is the initiator of the extrinsic clotting cascade. TF binds to plasma factor VII/VIIa (FVII/VIIa) to initiate coagulation via activation of Factor X (FX). This leads to the generation of thrombin, fibrin deposition and clot formation, as well as platelet activation (Fig. 1). In addition to its haemostatic role, TF activates cell signalling through TF:FVIIa and TF:FVIIa:FXa cleaving of the G-coupled protease-activated receptor (PARs) 1 and 2 complexes.

Fig. 1

The extrinsic coagulation pathway. Tissue Factor (TF), the main initiator of the coagulation cascade, complexes with Factor VIIa to activate Factor X, and in turn converts prothrombin (PT) to thrombin (Th) and ultimately fibrinogen to fibrin, with subsequent clot formation. FXa is inhibited by the direct oral anticoagulant Rivaroxaban. Thrombin also binds to protease-activated receptor 1 (PAR-1), and the TF/FVIIa/Xa complex to PAR-2. In cancer cells, this is proposed to result in pro-angiogenic, pro-proliferative and pro-invasive gene expression resulting in increased metastases. Figure created with [6]. Abbreviations: TF, Tissue Factor; FVIIa, activated Factor VII; FX, Factor X; FXa, activated Factor X; PT, prothrombin; Th, thrombin; PAR, protease-activated receptor

TF directly promotes tumour growth, migration and angiogenesis via activation of the PAR-2 receptor [7,8,9,10,11]. Thrombin can also modify tumour cell behaviour, directly through the activation of PAR receptors, indirectly by acting on stromal cells, or by the generation of fibrin matrices [12,13,14]. Thrombin promotes tumour growth in vitro [15] and in vivo [16,17,18], enhances tumour adhesion to platelets [16, 17, 19] and endothelial cells [20] in vitro and increases experimental (tail-vein injection) metastasis [16, 17, 19, 21]. Thrombin also increases tumour cell motility [22]. TF [23] and thrombin [24] promote neo-angiogenesis via upregulation of VEGF (a potent angiogenic factor) in cancer cells through the PI3K/Akt pathway [25]. TF also downregulates anti-angiogenic factors such as thrombospondin-1 and thrombospondin-2 [26], while thrombin upregulates matrix metalloproteinase-2 [27]. TF and thrombin also activate angiogenesis by clotting-dependent mechanisms through production (via thrombin) of polymerised fibrin which provides a scaffold around tumours to support and stimulate endothelial cell proliferation [28]. In clinical studies, TF expression correlates with VEGF expression and markers of angiogenesis [29], while prothrombin fragments (produced when prothrombin is converted to active thrombin) closely associate with areas of neo-angiogenesis at the tumour-stroma interface [30, 31].

Cancer cells express high levels of TF, thrombin and PARs [32, 33]. Breast cancer expression of TF has been reported to be an independent predictor of overall survival [34]. Plasma D-dimer (fibrin degradation by-product) is increased in breast cancer and correlates with tumour stage, poor prognosis molecular phenotypes oestrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER-2) positive [35, 36], circulating tumour cells [37, 38] and reduced survival [39]. D-dimer also has potential as a pharmacodynamic biomarker for chemotherapy response [40].

In a prospective cohort study of 248 early breast cancer patients, we found that tumour fibroblast expression of TF was increased in patients with primary breast cancer as compared to both ductal carcinoma in situ (DCIS) and normal breast. We also found that fibroblast TF, thrombin, PAR-1 and PAR-2 expression were increased in patients with ER-negative, HER-2-positive and high Ki67 tumours [41].

Inhibition of this coagulation cascade could therefore be a therapeutic option in breast cancer patients. A Cochrane review in 2011 reported that parenteral anticoagulation (with either unfractionated heparin or low molecular weight heparin) for patients with cancer, who have no therapeutic or prophylactic indication for anticoagulation, resulted in a statistically and clinically significant reduction in mortality at 24 months. This demonstrates a potential anti-cancer effect of anticoagulants in patients with better prognosis metastatic disease [42].

Direct oral anticoagulants (DOACs) inhibit thrombin (e.g. dabigatran etexilate (Pradaxa®)) or its activating enzyme Factor Xa (e.g. Rivaroxaban). DOACs have come into regular clinical use in the last decade for the prevention of VTE in orthopaedic surgery and of stroke in non-valvular atrial fibrillation [43, 44]. DOACs are also used for the treatment of primary or recurrent VTE. DOACs target a specific single enzyme within the extrinsic clotting pathway unlike the more widespread effects of heparins and vitamin K antagonists (Warfarin). A meta-analysis of randomised controlled trials of VTE-treatment with DOACs in cancer patients has indicated they are as safe and effective as conventional treatments [45].

Rivaroxaban was the first orally active direct Factor Xa inhibitor and, through inhibition of the Tissue Factor-Factor VIIa-Factor Xa complex, inhibits the conversion of prothrombin to thrombin [46]. Rivaroxaban is well absorbed from the gut and maximum inhibition of Factor Xa occurs 1 to 4 h after administration [47, 48]. Rivaroxaban has shown comparable safety to heparin for thromboprophylaxis after total hip replacements, with the convenience of oral dosing and reduced coagulation monitoring [49]. Rivaroxaban has the potential to downregulate the TF-FVIIa-FXa complex activation of PAR-2 and the subsequent tumour cell migration and production of pro-angiogenic and immune-modulating cytokines, chemokines and growth factors [10]. Rivaroxaban was chosen as the DOAC for this window-of-opportunity study as it inhibits the coagulation cascade at its origin and has a good safety profile. We have also found that Rivaroxaban inhibits cancer stem cell (CSC) activity in the in vitro functional CSC assay of mammosphere formation [50].

In summary, in vitro and in vivo evidence supports a potential inhibitory effect of anticoagulants on cancer growth through proliferative, cancer stem cell, angiogenic and metastatic processes. ER-negative early breast cancer patients have a relatively poorer prognosis and higher stage at diagnosis with an associated reduced disease-free survival. ER-negative early breast cancer patients also have fewer options for adjuvant therapy. Our previous data supports the hypothesis that the extrinsic clotting pathway is more upregulated in the ER-negative breast cancer subgroup as compared to ER-positive breast cancer, and thereby provides a potential therapeutic strategy.

To test a novel therapy in the adjuvant breast cancer setting would require thousands of patients, long follow-up and great expense. The alternative is the more novel ‘window-of-opportunity’ clinical trial design where drugs are tested over a short period, in the preoperative setting. Biomarkers are used as early markers for response and long-term outcome. Ki67 (tumour proliferation marker) is recognised as such a marker in trials of endocrine therapy. Short-term neoadjuvant studies have demonstrated that only 2 weeks of preoperative endocrine therapy induces changes in Ki67 which predicts for treatment benefit and long-term survival outcome [51]. By using biomarkers, we may be able to demonstrate the potential effectiveness of an anticoagulant in the clinical setting to support future larger adjuvant trials.

The TIP Trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients.


This study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 1).


The primary aim of the Thrombin Inhibition Preoperatively in Early Breast Cancer (TIP) trial is to determine whether preoperative administration of the oral Factor Xa inhibitor Rivaroxaban results in inhibition of tumour proliferation markers, as determined by a reduction in tumour Ki67 from baseline (pre-treatment) to post treatment (‘end-of-trial’, at time of surgical excision or repeat core biopsy prior to neoadjuvant chemotherapy), in ER-negative early breast cancer patients.

Study design

The TIP trial is a phase II preoperative window-of-opportunity randomised controlled trial of Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients.

This UK-based multi-centre study will randomise 88 eligible patients (1:1) to either Rivaroxaban 20 mg once daily (OD) or no treatment (control). Randomisation will be blinded to pathologists and data analysts, but not to patients or clinicians.

Sample size calculation

The trial is designed with a two-sided alpha level of 0.05 and an estimated 80% power to detect a 0.6 standard deviation (SD) reduction in percentage tissue expression of Ki67 in early breast cancer patients treated with Rivaroxaban. Based on a two-sample t test with this 80% power, 88 eligible patients are required. We will allow for a 10% drop out rate, and therefore, 8 extra patients (giving a total of 96 patients) may need to be recruited. Any patient that withdraws from the trial or does not have surgery or a repeat core biopsy following treatment will be removed from the study and replaced.


Females aged 18 years or over with newly diagnosed early-stage breast cancer (stages I–III) that have a tumour of size ≥ 10 mm and are oestrogen receptor negative (ER−) as defined by an ER QuickScore/Allred Score ≤ 5 will be eligible to participate in the TIP trial. Exclusion criteria include factors related to slow drug excretion (e.g. poor renal function), drug interactions (e.g. azole-antimycotics) and risk factors for bleeding (e.g. recent major surgery).

Screening for eligibility

Assessments for patient eligibility to participate in the trial are completed prior to patient randomisation. These include blood biochemistry, liver function tests, baseline tumour assessment as per National Health Service Breast Screening Programme guidelines [52] and histopathological core biopsy including ER/PR receptor status. An electronic screening log is used to record each patient screened for the trial (even if not approached) and whether or not they were recruited.


Patients will be randomly assigned (1:1) to either the control or intervention arm. Randomisation will be carried out centrally at the Liverpool Cancer Trials Centre (LCTC) based on pre-specified randomisation lists. The sequence of allocations is produced using the Stata package ralloc employing permutated block randomisation with block length of 4, 6 and 8. There are no stratification factors to be considered.

Intervention group

Patients randomised to the intervention arm will receive Rivaroxaban 20 mg once daily for 11–17 days after diagnosis, prior to further treatment in the form of surgery or neo-adjuvant chemotherapy (NAC). Patients with planned NAC consent to undergo a repeat core biopsy once the trial treatment period has been completed.

Rivaroxaban treatment is stopped 24 h (range 18–36 h) prior to surgery or repeat core biopsy before commencing NAC (Figs. 2 and 3). The dose of 20 mg OD was chosen as this is the licenced dose in the UK for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors [53]. No other concurrent neoadjuvant breast cancer or anticoagulant therapy is permitted.

Fig. 2

Thrombin Inhibition Preoperatively (TIP) in Early Breast Cancer Trial flow diagram. In this multi-centre study patients are randomised 1:1 20 mg Rivaroxaban once daily (OD): No Treatment. Randomisation is blinded to pathologists, research laboratory staff and data analysts, but not to patients and clinicians

Fig. 3

TIP Trial Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Abbreviations: mg, milligram; OD, once daily

All patients in the intervention arm will have an alert sticker placed in their notes to ensure that the medical team are aware that the patient has been anticoagulated and take all necessary precautions to minimise bleeding in the event of any residual anticoagulant effect.

Modifications to the rivaroxaban dose are not allowed; the intervention will simply be discontinued upon presentation with unacceptable toxicity.

Control group

Patients randomised to the control group will not receive any anticoagulant therapy between diagnosis and either surgery or repeat biopsy prior to commencing NAC. They will receive current standard of care.

The use of a blinded placebo plus usual care comparator was considered in trial design but was decided against given the TIP trial has a biological endpoint (Ki67). Clinicians (surgeons or radiologists performing biopsies) are not to be blinded as a safety measure, but laboratory staff and data analysts will be blinded to avoid bias.


Following randomisation, all patients receive a copy of their signed consent form, a patient information sheet and a patient contact card. Residual tissue from the formalin-fixed paraffin-embedded pre-treatment diagnostic core biopsy tissue which is routinely stored will be requested for trial purposes and a 35-ml venous blood sample collected.

Upon termination of Rivaroxaban treatment or none, residual formalin-fixed and fresh tumour tissue will be obtained from trial patients undergoing surgery after routine clinical processing or from the repeat research biopsy prior to NAC.

All post-trial care, including provision for compensation, is through the NHS standard care pathway and NHS channels.

Patient and public involvement

Patient and public representatives (PPI) were involved in the set-up of the trial, and a patient representative will take part in Trial Steering Committee meetings. PPI indicated to us that the trial risk was minimal and acceptable.


Pathologists, research laboratory staff and data analysts will be blinded to patient randomisation in the TIP trial for assessment of both primary and secondary outcome measures.

Primary outcome measure


The primary outcome measure of the TIP trial is to determine the absolute and percentage change in the tumour tissue expression of the biomarker Ki67 before and after Rivaroxaban treatment, with the control arm acting as a reference group.

The completely specified primary outcome measure as defined by the five elements set out by Saldanha et al. [54]: (1) Domain: Breast cancer tumour cell proliferation. (2) Specific measurement: Immunohistochemical assessment of the proportion (%) of cells staining for the nuclear antigen Ki67. (3) Metric: Absolute and percentage change from baseline. (4) Method of aggregation: Mean. (5) Time point: Post-treatment (‘end-of-trial’, 14 days range 11–17, at time of surgical excision or repeat core biopsy prior to neoadjuvant chemotherapy).

Secondary outcome measures

A range of potential breast cancer pharmacodynamic biomarkers will be studied as secondary outcome measures:

  1. 1.

    Primary mammosphere formation assays will be performed ex vivo on fresh tumour tissue at the end-of-trial time-point to determine cancer stem cell activity. This data will be presented as a comparison of the means of mammosphere forming efficiency (MFE) in the intervention and control arms. MFE is calculated by dividing the number of mammospheres formed at 7 days by the number of cells seeded [55].

  2. 2.

    Formalin-fixed paraffin-embedded (FFPE) tissue will be assessed for tumour markers of angiogenesis (CD31), apoptosis (Cleaved caspase 3, TUNEL) and the extrinsic clotting pathway (Tissue Factor, thrombin, PAR-1; in both epithelial cells/fibroblasts) by immunohistochemistry. Baseline core biopsy samples and end-of-trial biopsy samples will be assessed, and mean values analysed.

  3. 3.

    Plasma biomarkers of coagulation (Tissue Factor, thrombin and d-dimer) will be quantified by enzyme-linked immunosorbent assay (ELISA) with the change from baseline to the end-of-trial time-point assessed. Mean biomarker will be compared between the control and intervention arms.

  4. 4.

    FFPE tissue and plasma will be stored for future translational research, for example ctDNA, with patient consent.

Trial tumour tissue, plasma and serum samples, both for short-term storage and for future translational research, will be stored in temperature-controlled facilities at the Oglesby Cancer Research Building in Manchester, UK. This patient material will all be stored according to Good Clinical Laboratory Practise (GCLP) guidelines [56].


Both primary and secondary analyses will be carried out on an intention to treat (ITT) basis. Missing data or missing patients’ samples will be minimised by active monitoring by the Trial Coordinator, regularly reviewed by the Trial Management Group (TMG), including scheduled data cleaning, sample checking and communications with trial sites. If samples for the primary endpoint analysis are not collected, the patient will be replaced. Any patients who withdraw from the trial will be replaced. If the level of missing data exceeds these safeguards, it may be handled by multiple imputation. Separate multiple imputations by treatment arm would be performed, using the method of chained equations.


Manual Section Score Ki67 will be compared between arms using a beta regression model including terms accounting for baseline Ki67, treatment arm, and covariates known to be associated with Ki67 such as tumour grade and HER-2 status. Although the sample size is based on a t test, a beta regression model for the analysis is superior, partly because the analysis would be on the original scale, partly because covariates including baseline would be easily accounted for and partly because treatment effects on variance could be explicitly modelled. Ki67 measurements will be performed in accordance with national guidance [57].

Data management

The paper Case Report Form (CRF) distributed by the LCTU is the primary data collection instrument for the study and is completed by delegated site staff. The accuracy of these CRFs are the responsibility of the Principal Investigator at each site. CRF data is entered into an electronic database manually from the paper forms by LCTU staff. There is central monitoring by the LCTU to ensure that any data collected is compliant with the trial protocol. The database used for this trial includes validation features which will alert the user to certain inconsistent or missing data on data entry. Data stored at the LCTU will be checked for missing or unusual values (range checks) and checked for consistency over time. The LCTU will preserve the confidentiality of participants taking part in the study. Access to the final trial dataset is granted by the written authorisation of the Chief Investigator, CCK.

Participant retention and complete follow-up

The Trial Coordinator will produce reports on patient withdrawals, losses to follow-up and the quantity of missing CRFs/data across sites for review by LCTU business meetings, the Trial Management Group (TMG), Trial Steering Committee (TSC) and Independent Safety and Data Monitoring Committee (ISDMC). Any problems identified will be discussed and remedial action taken as necessary. Patients who withdraw from the trial will be replaced, and any who deviate will be managed on a case-by-case basis.

If a patient wishes to withdraw from trial treatment, this will be acted upon immediately and will cause no detrimental effect to them in receiving usual standard of care. Following end of study biopsy, a single safety follow-up is performed at ~ 2/52. There is no long-term follow-up within the trial. All long-term follow-up will be as per usual NHS practice.

Trial governance

Trial Coordinator (LCTU)

The LCTU will conduct central monitoring to ensure patient safety and that the trial procedures, trial intervention administration and laboratory and data collection processes meet both Sponsor and regulatory requirements. This includes ensuring that all regulatory and ethical approvals are in place before a site is opened, and generation of periodic Central Monitoring Reports for review by the Trial Management Group (TMG). The LCTU will carry out audits of trial sites and laboratories independent of the investigators and the Sponsor using set procedures after the first patient is recruited and after the tenth patient is recruited. The LCTU has a formalised Quality Management System in place for trial Quality Assurance.

Trial Management Group

The Trial Management Group (TMG) will comprise of the Chief Investigator, other lead investigators (clinical and non-clinical) and members of the LCTU. The TMG will be responsible for the day-to-day running and management of the trial and will meet approximately three times per year.

Trial Steering Committee

The Trial Steering Committee (TSC) includes a minimum of an independent Chairman; two additional independent expert members in the field of breast cancer (one being a statistician) and a lay/consumer representative, along with members of the Trial Management Group (TMG). Among other things, the TSC takes responsibility for monitoring and supervising the progress of the trial, considering recommendations from the Independent Safety and Data Monitoring Committee (IDSMC) and advising the TMG on all aspects of the trial as outlined in the TSC charter. Further details on the TIP Trial TSC charter can be obtained from the Trial Coordinator (

The ultimate decision for the continuation of the trial lies with the TSC, and the TSC may stop the trial before completion upon recommendation of the IDSMC.

Independent Data and Safety Monitoring Committee

The TIP Trial Independent Safety and Data Monitoring Committee (IDSMC) is a multidisciplinary group independent from the Sponsor and competing interests. The IDSMC consists of an independent chairperson with breast cancer and/or significant trial experience, plus two further independent members: one statistician and at least one clinician. They are responsible for safeguarding the interests of trial participants, with interim monitoring of the safety and efficacy of the interventions during the trial, and for monitoring the overall progress and conduct of the clinical trial as outlined in the IDSMC charter. Further details on the TIP Trial IDSMC charter can be obtained from the Trial Coordinator.

The IDSMC will first convene prior to the recruitment of the first patient and will then define the required frequency of subsequent meetings (at least annually). The IDSMC will provide a recommendation to the Trial Steering Committee concerning the continuation of the study.

Safety monitoring

Rivaroxaban is an oral anticoagulant, with an associated risk of bleeding, as with any anticoagulant. Unlike Warfarin, blood monitoring is not required. We will systemically collect data on all expected and unexpected adverse events at each study visit, with Principal Investigators required to assess and report them to the Trial Coordinator throughout the whole trial process, from trial entry through to follow-up. An adverse event term must be provided for each adverse event, using the terms listed in the Common Terminology Criteria for Adverse Events v4.03 [58]. Investigators must report serious adverse events (SAEs) within 24 h of the local site becoming aware of the event. Adverse events related to the study intervention will be reported in trial publications.

This study may be terminated at the request of the Chief Investigator, Independent Data and Safety Monitoring Committee or the Independent Ethics Committee if, during the course of the study, concerns about the safety emerge. Serious adverse events are relayed directly to the Chief Investigator via the Trial Coordinator, with all adverse events included in the Central Monitoring Reports reviewed at Trial Management Group meetings. Interim monitoring of safety is also carried out by the IDSMC. The report of a serious adverse reaction or multiple adverse reaction incidences (depending on severity) would constitute grounds for trial termination.


We aim to present the data at scientific and medical conferences and to publish the results in a peer-reviewed journal. Authorship guidelines will be as per Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals, International Committee of Medical Journal Editors (ICMJE) [59]. We have no intended use of professional writers.


Ki67 is recognised as a marker of tumour proliferation in trials of endocrine therapy. Short-term neoadjuvant studies have demonstrated that only 2 weeks of preoperative endocrine therapy induces changes in Ki67 which predicts for treatment benefit and long-term survival outcome [51]. By using biomarkers, we will be able to demonstrate the effectiveness of Rivaroxaban in the clinical setting within 5 years, thereby providing an improved clinical trials service to the patients recruited. However, the measurement of Ki67 has its challenges as there is substantial heterogeneity and variable levels of validity in methods of assessment [57]. It is agreed that we will use the immunohistochemistry (IHC) method for determining Ki67 percentages. The IHC staining and assessment of Ki67 will be performed on all trial samples in one batch upon trial completion in an attempt to minimise variability and increase accuracy.

The collection of fresh tumour tissue for mammosphere analysis will not always be feasible, particularly in patients with smaller tumours or who undergo a research biopsy. Mammosphere analysis is therefore a secondary and exploratory outcome of the TIP trial. However, if successful, it may allow assessment of the value of fresh tissue in ex vivo analysis as a biomarker of response.

This trial has been designed to minimise the chance of haematoma following surgery or biopsy in the presence of an anticoagulant. The terminal elimination half-life of Rivaroxaban is 5 to 9 h in healthy subjects aged 20 to 45 years and 11 to 13 h in elderly patients aged 60 to 76 years [60]. Clinical guidelines recommend stopping the drug in routine surgery patients at ≥ 24 h before surgery for minor risk procedures [61]; therefore, a safe time period, in patients with normal renal function, was taken as 24 h. However, clinicians (surgeons or radiologists performing biopsies) are still advised of the randomisation so bleeding precautions can be maximised.

The trial was initially designed as a window-of-opportunity pre-surgery study; however, with changing clinical practice, increasingly ER-negative patients are having neoadjuvant chemotherapy. Therefore, an amendment to the study was submitted to allow inclusion of neoadjuvant patients, with the post-trial biopsy being an additional research biopsy. It is routine to undergo radiological clip placement prior to commencement of chemotherapy, to allow identification of the tumour bed in the presence of complete radiological response to NAC. Therefore, to minimise impact on trial patients, the post-trial biopsy is performed at the time of clip placement. This was assessed as acceptable by our patient and public collaborators.

Trial status

Current protocol: Version 6, dated 10 October 2017

Important protocol modifications are communicated to relevant parties by the trial coordinator by direct communication and via the LCTU Portal

Recruitment start: June 2016

Expected recruitment end: September 2020

Open trial centres: Wythenshawe Hospital (Manchester), Royal Bolton Hospital, Royal Liverpool University Hospital, North Manchester General Hospital, St James’s University Hospital Leeds, Arrow Park Hospital/Clatterbridge Cancer Centre (Wirral), Churchill Hospital (Oxford); all United Kingdom.

Trial sponsor contact: Hayley Brooks, Oncology Clinical Trials Manager, Manchester University NHS Foundation Trust,

Availability of data and materials

Access to the final trial dataset will be granted by the written authorisation of the Chief Investigator, CCK.



Association of Breast Surgery


Cluster of differentiation 31


Direct oral anticoagulant (synonym: NOAC)


Digital Object Identifier


European Cancer Organisation


Enzyme-linked immunosorbent assay


Oestrogen receptor


European Clinical Trials Database Reference


Formalin-fixed paraffin-embedded


Factor VII (seven)


Activated Factor VII (seven)


Factor X (ten)


Activated Factor X (ten)


General Practitioner


Human epidermal growth factor receptor 2


Independent Data and Safety Monitoring Committee


International Standard Randomised Controlled Trials Number


Intension to treat


Liverpool Cancer Trials Centre


Cancer Research UK Liverpool Cancer Trials Unit


Manchester Cancer Research Centre


Mammosphere Forming Efficiency




Medicines and Healthcare Products Regulatory Agency


Neoadjuvant chemotherapy


National Institute for Health Research


Novel oral anticoagulant (synonym: DOAC)


National Research Ethics Service


Once daily


(1/2) protease activated receptor


Patient and public input




Research Ethics Committee


Tissue Factor


Thrombin Inhibition Preoperatively in Early Breast Cancer


Trial Management Group


Trial Steering Committee


Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling


Vascular endothelial growth factor


Venous thromboembolism


  1. 1.

    Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13.

    PubMed  Google Scholar 

  2. 2.

    Cronin-Fenton DP, Sondergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010;103(7):947–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008;99(7):1000–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Jones A, Stockton DL, Simpson AJ, Murchison JT. Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy. Br J Cancer. 2009;101(5):840–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. Anticancer Res. 2011;31(6):2383–8.

    PubMed  Google Scholar 

  6. 6.

    BioRender, a web-based tool for life-science and medical illustration. Toronto, Canada. Available from: Accessed 16 Apr 2020.

  7. 7.

    Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A. 2006;103(38):13932–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Ruf W. Tissue factor and cancer. Thromb Res. 2012;130(Suppl 1):S84–7.

    PubMed  Google Scholar 

  9. 9.

    Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006;66(1):307–14.

    CAS  PubMed  Google Scholar 

  10. 10.

    Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29):4834–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103(8):3029–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–64.

    CAS  PubMed  Google Scholar 

  13. 13.

    Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800–14.

    CAS  PubMed  Google Scholar 

  14. 14.

    Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–904.

    CAS  PubMed  Google Scholar 

  15. 15.

    Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood. 2000;95(10):3133–8.

    CAS  PubMed  Google Scholar 

  16. 16.

    Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest. 1991;87(1):229–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 1992;52(12):3267–72.

    CAS  PubMed  Google Scholar 

  18. 18.

    Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood. 1998;92(10):3694–700.

    CAS  PubMed  Google Scholar 

  19. 19.

    Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res. 1992;68(3):233–45.

    CAS  PubMed  Google Scholar 

  20. 20.

    Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993;53(6):978–82.

    CAS  PubMed  Google Scholar 

  21. 21.

    Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer. 1993;54(5):793–806.

    CAS  PubMed  Google Scholar 

  22. 22.

    Asanuma K, Wakabayashi H, Hayashi T, Okuyama N, Seto M, Matsumine A, et al. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology. 2004;67(2):166–73.

    CAS  PubMed  Google Scholar 

  23. 23.

    Zhang J, Ding J, Zhang X, Shao X, Hao Z. Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue factor (TF) in SGC-7901 gastric cancer cells. Cancer Biol Ther. 2005;4(7):769–72.

    CAS  PubMed  Google Scholar 

  24. 24.

    Liu J, Schuff-Werner P, Steiner M. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem Biophys Res Commun. 2006;343(1):183–9.

    CAS  PubMed  Google Scholar 

  25. 25.

    Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734–41.

    CAS  PubMed  Google Scholar 

  27. 27.

    Maragoudakis ME, Kraniti N, Giannopoulou E, Alexopoulos K, Matsoukas J. Modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and antagonists. Endothelium. 2001;8(3):195–205.

    CAS  PubMed  Google Scholar 

  28. 28.

    van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci. 2001;936:426–37.

    PubMed  Google Scholar 

  29. 29.

    Carneiro-Lobo TC, Lima MT, Mariano-Oliveira A, Dutra-Oliveira A, Oba-Shinjo SM, Marie SK, et al. Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients. Oncol Rep. 2014;31(2):679–86.

    CAS  PubMed  Google Scholar 

  30. 30.

    Wojtukiewicz MZ, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Rozanska-Kudelska M, et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res. 2000;97(5):335–42.

    CAS  PubMed  Google Scholar 

  31. 31.

    Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost. 2003;29(3):291–300.

    CAS  PubMed  Google Scholar 

  32. 32.

    Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost. 2006;32(1):54–70.

    CAS  PubMed  Google Scholar 

  33. 33.

    Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood. 2004;104(9):2746–51.

    CAS  PubMed  Google Scholar 

  34. 34.

    Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83(2):164–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18(3):600–8.

    CAS  PubMed  Google Scholar 

  36. 36.

    Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res. 2004;10(12 Pt 1):4083–8.

    CAS  PubMed  Google Scholar 

  37. 37.

    Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, et al. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015;113(3):593–8.

    PubMed  Google Scholar 

  38. 38.

    Kirwan CC, Descamps T, Castle J. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. Clin Transl Oncol. 2019;22(6):870–7.

  39. 39.

    Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267–72.

    CAS  PubMed  Google Scholar 

  40. 40.

    Kirwan CC, McCollum CN, McDowell G, Byrne GJ. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. Clin Appl Thromb Hemost. 2015;21(5):420–7.

    CAS  PubMed  Google Scholar 

  41. 41.

    Shaker H, Bundred NJ, Landberg G, Pritchard SA, Albadry H, Nicholson SL, et al. Breast cancer stromal clotting activation (Tissue Factor and thrombin): a pre-invasive phenomena that is prognostic in invasion. Cancer Med. 2020;9(5):1768–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Akl EA, Gunukula S, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2011;(4):CD006652.

  43. 43.

    Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One. 2016;11(8):e0160064.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88–94.

    PubMed  Google Scholar 

  45. 45.

    Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147(2):475–83.

    PubMed  Google Scholar 

  46. 46.

    Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900–8.

    CAS  PubMed  Google Scholar 

  47. 47.

    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412–21.

    CAS  PubMed  Google Scholar 

  48. 48.

    Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873–80.

    CAS  PubMed  Google Scholar 

  49. 49.

    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22):2374–81.

    CAS  PubMed  Google Scholar 

  50. 50.

    Castle J, Farnie G, Kirwan CC. PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation. Thromb Res. 2016;140(Suppl 1):S180.

    PubMed  Google Scholar 

  51. 51.

    Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):951s–8s.

    CAS  PubMed  Google Scholar 

  52. 52.

    Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. The Royal College of Pathologists; 2016. Accessed 17 Apr 2020.

  53. 53.

    Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, et al. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010;134(6):964–9.

    CAS  PubMed  Google Scholar 

  54. 54.

    Saldanha IJ, Dickersin K, Wang X, Li T. Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability. PLoS One. 2014;9(10):e109400.

    PubMed  PubMed Central  Google Scholar 

  55. 55.

    Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012;17(2):111–7.

    PubMed  Google Scholar 

  56. 56.

    Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, Hitchcock R, et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal. 2008;46(1):18–29.

    CAS  PubMed  Google Scholar 

  57. 57.

    Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2011;103(22):1656–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58.

    National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Available from: Accessed 22 July 2020.

  59. 59.

    (ICMJE) ICoMJE. Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals. Available from: Accessed 22 July 2020.

  60. 60.

    National Institute for Clinical Excellence (NICE) Rivaroxaban Indications and Dose. Available from: Accessed 11 July 2019.

  61. 61.

    Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg. 2014;101(7):742–9.

    CAS  PubMed  Google Scholar 

Download references


The TIP Trial is coordinated by Helen Scott from the LCTU, with support from Manchester University NHS Foundation Trust Sponsor representative Hayley Brook. Sample collection is supported by the MCRC Biobank.

The Principal Investigators at each trial site are Cliona Kirwan (Wythenshawe Hospital), Christopher Holcombe (Royal Liverpool University Hospital), Angela Volleamere (Royal Bolton Hospital), Maria Bramley (North Manchester General Hospital), Jalal Kokan (Macclesfield District General Hospital), Pankaj Gupta Roy (Oxford Churchill Hospital), Rajgopal Achuthan (St James’s University Hospital Leeds) and Raman Vinayagam (Clatterbridge Hospital Wirral).


This trial is funded by a National Institute for Health Research (NIHR) Clinician Scientist award and the NIHR Clinical Research Network. It is supported by The University of Manchester, the Association of Breast Surgery (ABS) and a European Cancer Organisation (ECCO) Fellowship Grant (Joint ECCO-AACR-EORTC-ESMO Workshop ‘Methods in Clinical cancer Research’). Ultimate authority in the study design, collection, management, analysis, interpretation of data, writing of the report and the decision to submit the report for publication remains with the Chief Investigator CCK.

Author information




CCK, JC and EB were the major contributors in writing the manuscript. SC provided statistical guidance for the trial. All authors read and approved the final abstract.

Authors’ information

CCK is a Clinician Scientist in Surgical Oncology, Royal College of Surgeons of England Professor of Surgical Trials and Consultant Oncoplastic Breast Surgeon based at the Manchester Cancer Research Centre, with clinical work at The Nightingale Centre at Wythenshawe Hospital, UK. She is the Chief Investigator of the TIP trial and may be contacted for Public and Scientific Queries at

Corresponding author

Correspondence to Cliona C. Kirwan.

Ethics declarations

Ethics approval and consent to participate

This study has UK National Research Ethics Service (NRES) approval REC reference 15/NW/0406 from the North West - Liverpool Central Research Ethics Committee. Patients must give written informed consent via the document-controlled trial consent form before undergoing any trial-specific screening investigations. Trial sites are responsible for assessing a patient’s capability to give informed consent and ensuring an appropriate member of staff has countersigned and dated the consent form. Patients with planned NAC must consent to undergo a repeat core biopsy once treatment has been completed. Patients will be asked to consent that data are recorded, collected, stored and processed in accordance with the EU Data Protection Directive (95/46/EC). Patients at consent may give permission for stored tissue and/or blood samples to be used for future breast cancer research, which is optional for TIP trial participation. The TIP trial coordinator confirms that eligibility criteria are met, that informed consent is obtained and that these are both documented.

This study may be terminated at the request of the Chief Investigator, Independent Data and Safety Monitoring Committee or the Independent Ethics Committee if, during the course of the study, concerns about the safety emerge.

Consent for publication

Not applicable. No intended sharing of deidentified individual clinical trial participant-level data (IPD).

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Castle, J., Blower, E., Bundred, N.J. et al. Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. Trials 21, 749 (2020).

Download citation


  • Tissue Factor
  • Thrombin
  • FXa
  • DOAC
  • NOAC
  • Rivaroxaban
  • Breast cancer
  • Clinical trial
  • Ki67